Drug development, from the initial discovery of a promising target to commercial launch, is an expensive, lengthy, and high-risk affair with poor success in the clinics. It is an even bigger struggle for emerging pharma companies (often the innovative engines for many of today’s novel products), given their lack of resources and facilities in an increasingly competitive market.

With a growing focus on early development to avoid late-stage attrition, contract development and manufacturing organizations (CDMOs) a r e increasingly becoming critical components to help overcome these challenges. CDMOs with end-to-end expertise can help pharma companies develop strategies to achieve clinical success while ensuring time and cost efficiencies.

This article discusses the key strategies adopted by leading CDMO Syngene to accelerate the lead to first-in-human (FIH) clinical trial journey of small molecules for clients.